U.S. Paper and Forestry Products Stock News

Fidelity National Financial (FNF) has just wrapped up FY 2025 with Q4 revenue of US$4.1b and a basic EPS loss of US$0.43, while trailing 12 month figures show revenue of US$14.5b and basic EPS of US$2.22. Over recent quarters, the company has seen revenue move from US$3.0b in Q1 2025 to over US$4.0b in Q4, with quarterly EPS ranging from US$0.30 to US$1.33 before the latest loss, creating a mixed picture on profitability. For investors, that combination of solid top line, uneven EPS and...

Chegg (CHGG) has just posted its FY 2025 numbers, with fourth quarter revenue of US$72.7 million and a basic EPS loss of US$0.30, while trailing twelve month revenue came in at US$376.9 million with a basic EPS loss of US$0.96. Over recent quarters, revenue has moved from US$143.5 million in Q4 2024 to US$121.4 million in Q1 2025, US$105.1 million in Q2 2025, US$77.7 million in Q3 2025 and US$72.7 million in Q4 2025, alongside quarterly basic EPS losses ranging between US$0.06 and US$0.33...

Lucky Strike Entertainment (LUCK) just posted Q2 2026 results with revenue of US$306.9 million and a basic EPS loss of US$0.11, alongside net income excluding extra items of a US$15.1 million loss, keeping the focus squarely on how quickly the business can close the gap to profitability. The company has seen quarterly revenue move from US$300.1 million in Q2 2025 to US$306.9 million in Q2 2026, while basic EPS has shifted from a profit of US$0.17 to a loss of US$0.11 over the same period,...

Xeris Biopharma Holdings (NasdaqGS:XERS) just closed FY 2025 with Q4 revenue of US$85.8 million and basic EPS of US$0.07, backed by net income of US$11.1 million. The company has seen quarterly revenue move from US$54.3 million in Q3 2024 to US$60.1 million in Q4 2024, then to US$60.1 million in Q1 2025, US$71.5 million in Q2 2025, US$74.4 million in Q3 2025, and US$85.8 million in Q4 2025, while EPS shifted from a loss of US$0.11 in Q3 2024 to EPS of US$0.07 in Q4 2025. With trailing twelve...

LTC Properties (LTC) has just wrapped up FY 2025 with fourth quarter revenue of US$82.5 million, basic EPS of US$2.14, and funds from operations of US$34.9 million, giving investors a clear view of its latest run rate. Over the past year, revenue across the trailing twelve months moved from US$201.6 million to US$257.6 million, while basic EPS over the same window went from US$2.07 to US$2.54. This sets the backdrop for how you might think about the current report and its implications for...

McDonald's (MCD) closed out FY 2025 with Q4 revenue of US$7.0b and basic EPS of US$3.03, while trailing 12 month revenue reached US$26.9b and EPS came in at US$12.00. Over recent periods the company has seen quarterly revenue move from US$6.4b in Q4 2024 to US$7.1b in Q3 2025 before Q4’s US$7.0b, alongside quarterly EPS ranging between US$2.80 and just over US$3.19. With trailing net income of US$8.6b and margins reported in the low 30% range, investors are looking at a business that is...

Peloton Interactive (PTON) just posted Q2 2026 results with revenue of US$656.5 million and a net loss of US$38.8 million, translating to basic EPS of a US$0.09 loss, while the trailing twelve months show revenue of US$2.4 billion and a net loss of US$50.9 million, or basic EPS of a US$0.12 loss. Over recent quarters, revenue has moved from US$673.9 million in Q2 2025 to US$656.5 million in Q2 2026, while quarterly basic EPS has ranged from a loss of US$0.24 in Q2 2025 to a profit of US$0.05...

Matador Resources FY 2025 earnings snapshot Matador Resources (MTDR) has just wrapped up FY 2025 with fourth quarter revenue of US$1,008.7 million and basic EPS of US$1.55, alongside net income from ongoing operations of US$192.5 million. Across the year, the company has seen quarterly revenue range from US$852.5 million to US$1,008.7 million, with EPS between US$1.21 and US$1.92, giving investors a clear line of sight on how the top and bottom line have translated into profit over time. With...

Vital Farms has reported past Q1 2026 results showing sales rising to US$187.16 million from US$162.19 million, but swinging from a US$16.9 million profit to a US$1.52 million net loss alongside an employee stock plan shelf registration of about US$26.88 million. At the same time, Vital Farms is winding down its butter line, managing egg oversupply, and facing multiple lawsuits tied to alleged ERP-related disclosure issues, all of which could influence how investors view its core egg-focused...

PayPal Holdings (PYPL) opened 2026 with Q1 revenue of US$8.4b and basic EPS of US$1.22, setting the tone against a backdrop of steady profit generation over the past year. Over the last 12 months, trailing revenue sat at US$33.7b with basic EPS of US$5.38, and earnings growth of 11.3% paired with a net margin of 15% gives investors a results set where profitability and efficiency sit at the center of the story. See our full analysis for PayPal Holdings. With the headline numbers on the table,...

Curious whether BrightSpring Health Services at US$52.74 is offering value or just riding hype? This article walks you through what the current price could mean for you as an investor. The stock has returned 9.5% over the past week, 21.2% over the last 30 days, 37.3% year to date and 128.9% over the past year. This naturally raises questions about how much of the story is already reflected in the price. Recent attention around BrightSpring Health Services has centered on its position in the...

If you are wondering whether Six Flags Entertainment is attractively priced today or a potential value trap in disguise, this article breaks down what the current share price is really offering you. The stock last closed at US$19.69, with returns of 9.3% over the past week, 10.1% over the past month, 27.1% year to date, and a 45.5% decline over the past year as well as 52.2% and 54.1% declines over the last 3 and 5 years. Recent headlines around Six Flags Entertainment have focused on its...

A federal judge has allowed key investor fraud claims against Scotts Miracle-Gro (NYSE:SMG) to proceed, focusing on alleged misstatements around demand, inventory, and the Hawthorne cannabis unit. The ruling keeps senior management and the company under legal scrutiny, extending an ongoing securities lawsuit rather than dismissing it outright. This development adds a layer of litigation and governance risk that sits alongside existing discussions of earnings, debt, and recovery efforts. For...

Lumen Technologies (LUMN) opened Q1 2026 with revenue of US$2.9 billion and a basic EPS loss of US$0.20, alongside net income excluding extra items of a US$200 million loss. Over recent quarters, revenue moved from US$3.3 billion in Q4 2024 to US$3.2 billion in Q1 2025 and US$3.0 billion in Q4 2025. Basic EPS shifted from a profit of US$0.09 in Q4 2024 to losses of US$0.20 in Q1 2025 and US$0.00 in Q4 2025. Taken together, these figures frame Q1 2026 as another period where investors are...

Adaptive Biotechnologies (ADPT) opened Q1 2026 with revenue of US$70.9 million and a basic EPS loss of US$0.13, alongside a net loss of US$20.0 million. Over recent quarters the company has seen revenue move from US$47.5 million in Q4 2024 to US$52.4 million in Q1 2025, US$58.9 million in Q2 2025, US$94.0 million in Q3 2025 and US$71.7 million in Q4 2025. Quarterly EPS ranged from a loss of US$0.23 in Q4 2024 to a profit of US$0.06 in Q3 2025 and back to a loss of US$0.09 in Q4 2025, putting...

The RMR Group Inc. has reported past second-quarter 2026 results, with sales rising to US$5.1 million while revenue fell to US$145.63 million, and quarterly net income declining to US$1.01 million, or US$0.05 per diluted share, compared with the prior year period. Over the first six months of fiscal 2026, higher sales but lower revenue coincided with net income improving to US$13.2 million, highlighting a contrast between weaker quarterly profitability and stronger year‑to‑date earnings. We...

Wondering if Robinhood Markets at around US$79 per share is still compelling value or if the easy gains are behind it? This article breaks down what the current price really reflects. The stock has been volatile recently, with an 11% return over the last 7 days, 13.3% over the last 30 days, a 31.4% decline year to date, and a 58.1% return over the last year, which can shift how the market is thinking about both opportunity and risk. Recent coverage has focused on Robinhood's evolving role in...

What recent moves in Veradermics (MANE) might be telling you Veradermics (MANE) has drawn attention after a sharp month return of about 72% and a very large past 3 months move, putting its clinical stage dermatology pipeline and valuation in sharper focus for investors. See our latest analysis for Veradermics. The recent 72% 30 day share price return and very large 90 day move sit alongside a 190.78% year to date share price return, which points to strong upward momentum despite a 4.38% one...

Investors may be wondering whether United Therapeutics at around US$596.76 is still offering value after a strong run, or if the easy gains are already behind it. The stock has recent returns of 4.5% over 7 days, 6.6% over 30 days, 20.1% year to date, 94.4% over 1 year and 181.2% over 3 years. This puts valuation questions front and center for anyone considering it today. Recent coverage has focused on United Therapeutics as a high growth biotech with a strong pipeline and regulatory...

Pool Corporation (NasdaqGS:POOL) has announced the immediate departure of CEO Peter D. Arvan. John B. Watwood has been appointed as the new President and CEO, with John E. Stokely becoming Executive Chair. The company has postponed its upcoming Investor Day following the leadership change. Pool enters this leadership transition after a period of weak share price performance, with NasdaqGS:POOL at $188.09 and showing a 10.3% decline over the past week and 35.2% decline over the past year...

Centrus Energy (LEU) opened Q1 2026 with revenue of US$76.7 million and basic EPS of US$0.51, against a backdrop of forecast earnings growth of about 7.0% a year and revenue growth around 5.1%. Over recent quarters the company has seen revenue range between US$73.1 million and US$154.5 million with basic EPS between US$0.21 and US$3.21. Trailing 12 month EPS sits at US$3.25 on revenue of US$452.3 million and net income of US$60.6 million, framing a set of results where profit growth and...

In late April 2026, Glaukos Corporation reported first‑quarter 2026 sales of US$150.57 million, a rise from US$106.66 million a year earlier, alongside a net loss of US$19.78 million, and raised its 2026 net sales guidance to a range of US$620 million to US$635 million. At the same time, Glaukos highlighted a broadened ophthalmic portfolio and long-term growth plan, even as insider share sales and continued losses underline ongoing execution and commercialization risks. We’ll now explore how...

Wondering if MKS at around US$293.77 is still offering value after a strong run, or if you might be turning up late to the story. The stock has posted returns of 10.7% over 7 days, 24.0% over 30 days, 74.5% year to date, 298.2% over 1 year and 255.7% over 3 years, with a 5 year return of 83.9%. These moves have kept MKS firmly on investors' radars, as sustained share price strength often raises questions about how the current price lines up with underlying fundamentals. With this context in...

What recent performance signals for Omeros (OMER) Without a single defining headline driving trading, Omeros (OMER) has still drawn attention after a strong month and past 3 months, alongside sizeable 1 year and 3 year total returns. At a recent price of $14.83 and a market cap of about $1.06b, the stock reflects a clinical stage pipeline built around immunologic and rare disease programs rather than current product revenue. See our latest analysis for Omeros. For context, Omeros has paired a...